Your browser doesn't support javascript.
loading
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.
Hashmi, Shahrukh K; Lee, Stephanie J; Savani, Bipin N; Burns, Linda; Wingard, John R; Perales, Miguel-Angel; Palmer, Jeanne; Chow, Eric; Meyer, Everett; Marks, David; Mohty, Mohamad; Inamoto, Yoshihiro; Rodriguez, Cesar; Nagler, Arnon; Sauter, Craig; Komanduri, Krishna V; Pidala, Joseph; Hamadani, Mehdi; Johnston, Laura; Shah, Nina; Shaughnessy, Paul; Hamilton, Betty K; Majhail, Navneet; Kharfan-Dabaja, Mohamed A; Schriber, Jeff; DeFilipp, Zachariah; Tarlock, Katherine G; Fanning, Suzanne; Curtin, Peter; Rizzo, J Douglas; Carpenter, Paul A.
Afiliação
  • Hashmi SK; King Faisal Hospital and Research Center, Riyadh, Saudi Arabia; Mayo Clinic, Rochester, Minnesota.
  • Lee SJ; Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Savani BN; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Burns L; National Marrow Donor Program/Be The Match, Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
  • Wingard JR; University of Florida, Gainesville, Florida.
  • Perales MA; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Palmer J; Mayo Clinic, Phoenix, Arizona.
  • Chow E; Fred Hutchinson Cancer Research Center, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington.
  • Meyer E; Stanford University Medical Center, Stanford, California.
  • Marks D; University Hospitals Bristol, Bristol, United Kingdom.
  • Mohty M; Saint-Antoine Hospital, INSERM UMRs U938, Paris, France.
  • Inamoto Y; National Cancer Center Hospital, Tokyo, Japan.
  • Rodriguez C; Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
  • Nagler A; Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Sauter C; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Komanduri KV; University of Miami Health System, Miami, Florida.
  • Pidala J; Moffitt Cancer Center, Tampa, Florida.
  • Hamadani M; Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Johnston L; Stanford University Medical Center, Stanford, California.
  • Shah N; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Shaughnessy P; Texas Transplant Institute, San Antonio, Texas.
  • Hamilton BK; Cleveland Clinic, Cleveland, Ohio.
  • Majhail N; Cleveland Clinic, Cleveland, Ohio.
  • Kharfan-Dabaja MA; Mayo Clinic, Jacksonville, Florida.
  • Schriber J; Honor Health, Scottsdale, Arizona.
  • DeFilipp Z; Massachusetts General Hospital, Boston, Massachusetts.
  • Tarlock KG; Seattle Children's Hospital, Seattle, Washington.
  • Fanning S; Greenville Health System Cancer Institute, Greenville, South Carolina.
  • Curtin P; Moores Cancer Center, University of California, La Jolla, San Diego, California.
  • Rizzo JD; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Carpenter PA; Fred Hutchinson Cancer Research Center, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington. Electronic address: pcarpent@fredhutch.org.
Biol Blood Marrow Transplant ; 24(6): 1119-1124, 2018 06.
Article em En | MEDLINE | ID: mdl-29608957
ABSTRACT
Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because of unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evaluate current survivorship or long-term follow-up (LTFU) clinics specifically for HCT survivors and to evaluate the potential barriers in their establishment, the American Society for Blood and Marrow Transplantation (ASBMT) Practice Guidelines Committee electronically surveyed 200 HCT programs to gather quantitative and qualitative data about models of care. Among 77 programs (38.5%) that responded, 45% indicated presence of an LTFU clinic; however, LTFU care models varied with respect to services provided, specialist availability, type of patients served, and staffing. Among 55% of programs without an LTFU clinic, 100% agreed that allogeneic HCT survivors have unique needs separate from graft-versus-host disease and that complications could arise during the transition of care either from pediatric to adult settings or away from the HCT center. Lack of expertise, logistics, financial issues, and the observation that 84% of individual practitioners prefer to provide survivorship care were the identified obstacles to establishing new LTFU clinics. The ASBMT hopes that policymakers, HCT providers, and institutions will benefit from the results of this survey and recommends that delivering guidelines-driven screening and expert management of late effects is the goal of first-rate HCT survivorship care.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Assistência de Longa Duração / Sobreviventes / Transplante de Células-Tronco Hematopoéticas / Atenção à Saúde Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Assistência de Longa Duração / Sobreviventes / Transplante de Células-Tronco Hematopoéticas / Atenção à Saúde Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article